| Host: | Rabbit | 
| Applications: | WB/ELISA | 
| Reactivity: | Human | 
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. | 
| Clonality : | Monoclonal | 
| Clone ID : | SRM | 
| Conjugation: | Unconjugated | 
| Isotype: | IgG | 
| Formulation: | PBS with 0.05% Proclin300, 0.05% BSA, 50% Glycerol, pH 7.3. | 
| Purification: | Affinity purification | 
| Concentration: | Lot specific | 
| Dilution Range: | WB:1:500-1:1000ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. | 
| Gene Symbol: | ADSL | 
| Gene ID: | 158 | 
| Uniprot ID: | PUR8_HUMAN | 
| Immunogen Region: | 1-484 aa | 
| Specificity: | Recombinant fusion protein containing a sequence corresponding to amino acids 1-484 of human ADSL (NP_000017.1). | 
| Immunogen Sequence: | MAAGGDHGSPDSYRSPLASR YASPEMCFVFSDRYKFRTWR QLWLWLAEAEQTLGLPITDE QIQEMKSNLENIDFKMAAEE EKRLRHDVMAHVHTFGHCCP KAAGIIHLGATSCYVGDNTD LIILRNALDLLLPKLARVIS RLADFAKERASLPTLGFTHF QPAQLTTVGKRCCLWIQDLC MDLQNLKRVRDDLRFRGVKG TTGTQASFLQLFEGDDHKVE QLDKMVTEKAGFKRAFIIT | 
| Tissue Specificity | Ubiquitously expressed. Both isoforms are produced by all tissues. Isoform 2 is 10-fold less abundant than isoform 1. | 
| Function | Catalyzes two non-sequential steps in de novo AMP synthesis: converts (S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido)succinate (SAICAR) to fumarate plus 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide, and thereby also contributes to de novo IMP synthesis, and converts succinyladenosine monophosphate (SAMP) to AMP and fumarate. | 
| Protein Name | Adenylosuccinate LyaseAdslAslAdenylosuccinaseAsase | 
| Database Links | Reactome: R-HSA-73817 | 
| Alternative Antibody Names | Anti-Adenylosuccinate Lyase antibodyAnti-Adsl antibodyAnti-Asl antibodyAnti-Adenylosuccinase antibodyAnti-Asase antibodyAnti-ADSL antibodyAnti-AMPS antibody | 
Information sourced from Uniprot.org
                    
                
